Fecal DNA Testing for Colorectal Cancer Screening

Area of Science:

• Oncology
• Gastroenterology
• Molecular Diagnostics

Background:

• Colorectal cancer (CRC) screening is crucial for early detection and improved patient outcomes.
• Noninvasive strategies like fecal DNA examination are recommended for average-risk individuals.
• Fecal DNA tests detect neoplastic DNA shed from colonic lesions.

Purpose of the Study:

• To evaluate the performance of an optimized multitarget stool DNA (mt-sDNA) test for colorectal cancer screening.
• To compare the efficacy of mt-sDNA testing with fecal immunochemical testing (FIT) and colonoscopy.

Main Methods:

• Cross-sectional validation studies were conducted to assess the performance of the mt-sDNA test.
• The study compared sensitivity and specificity for detecting CRC, advanced adenomas, and sessile serrated polyps.

Main Results:

• The mt-sDNA test demonstrated 92% sensitivity for CRC detection, significantly higher than FIT (74%).
• mt-sDNA showed higher detection rates for advanced adenomas (42% vs. 24%) and sessile serrated polyps (42% vs. 5%) compared to FIT.
• Overall specificity for all lesions was lower for mt-sDNA (87%) than FIT (95%).

Conclusions:

• The mt-sDNA test offers high sensitivity for CRC and precancerous lesion detection.
• Enhancements in cost-effectiveness or polyp detection sensitivity are needed for optimal implementation.
• Noninvasive fecal DNA screening holds potential to increase national screening rates due to patient convenience.